Junhong Li

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Epithelial Mesenchymal Transition

Induced Apoptosis

Radical Prostatectomy

Top Venues

Molecular carcinogenesis

This page only lists publications with an associated author ORCID identifier.

Publications

Junhong Li, Zongyuan Hong, Junyu Zhang, Shengfeng Zheng, Fangning Wan, Zheng Liu, Bo Dai
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene 43 (10) (2024)
Junhong Li, Zongyuan Hong, Junyu Zhang, Shengfeng Zheng, Fangning Wan, Zheng Liu, Bo Dai
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene 43 (10) (2024)
Junhong Li, Zongyuan Hong, Junyu Zhang, Shengfeng Zheng, Fangning Wan, Zheng Liu, Bo Dai
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene 43 (10) (2024)
Junhong Li, Zongyuan Hong, Junyu Zhang, Shengfeng Zheng, Fangning Wan, Zheng Liu, Bo Dai
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene 43 (10) (2024)
Junhong Li, Zongyuan Hong, Junyu Zhang, Shengfeng Zheng, Fangning Wan, Zheng Liu, Bo Dai
Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene (2024)
Junhong Li, Fangning Wan, Junyu Zhang, Shengfeng Zheng, Yunjie Yang, Zhe Hong, Bo Dai
Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling. Molecular carcinogenesis (2023)